300529 Share Price Performance
CN¥22.21
-15.61 (-41.27%)
Price CN¥22.21
Share PriceCN¥22.21
Does Jafron BiomedicalLtd (SZSE:300529) Have A Healthy Balance Sheet?
Mar 02
Jafron Biomedical Co.,Ltd. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 2 Fair Values set on narratives written by author
300529 Community Narratives
There are no narratives available yet.
Jafron Biomedical Co.,Ltd. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Oct 30, 2025
- Earnings per share (EPS)
- 0.85
- Gross Margin
- 79.95%
- Net Profit Margin
- 28.38%
- Debt/Equity Ratio
- 44.6%
Jafron Biomedical Co.,Ltd. Competitors
Snowflake Analysis
About 300529
- Founded
- 1989
- Employees
- 2500
- CEO
- WebsiteView website
Jafron Biomedical Co.,Ltd. engages in the research, development, production, and sales of blood purification products for hemadsorption field in worldwide. The company provides solutions for ESRD diseases, acute poisoning, critical illness, hepatopathy, immunological disorders, kidney, and liver diseases. It offers HA series hemoperfusion cartridge, BS series bilirubin adsorption column and DNA immunoadsorption column, hemoperfusion machine, and blood purification machine; and other products, such as hemodialyzer, disinfectants, hemodialysis concentrate, resin bandages, online hemodialysis powder bag/bucket, and adsorbable suture with needles, as well as syringe and infusion pumps. The company was founded in 1989 and is based in Zhuhai, China.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
Chinese Market Performance
- 7 Days: 1.8%
- 3 Months: 18.3%
- 1 Year: 24.1%
- Year to Date: 26.2%
In the last week, the market is up 1.8% led by Industrials sector. In the last year, the market has climbed 24%. As for the next few years, earnings are expected to grow by 27% per annum. Market details ›